Free Trial

Aclaris Therapeutics (ACRS) Competitors

Aclaris Therapeutics logo
$1.54 +0.09 (+6.21%)
Closing price 04:00 PM Eastern
Extended Trading
$1.59 +0.05 (+3.51%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACRS vs. PHAT, RLAY, ABUS, TNGX, CDXC, DNTH, MENS, MGTX, UPB, and XNCR

Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Phathom Pharmaceuticals (PHAT), Relay Therapeutics (RLAY), Arbutus Biopharma (ABUS), Tango Therapeutics (TNGX), ChromaDex (CDXC), Dianthus Therapeutics (DNTH), Jyong Biotech (MENS), MeiraGTx (MGTX), Upstream Bio (UPB), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.

Aclaris Therapeutics vs. Its Competitors

Aclaris Therapeutics (NASDAQ:ACRS) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Aclaris Therapeutics currently has a consensus price target of $9.71, indicating a potential upside of 530.80%. Phathom Pharmaceuticals has a consensus price target of $17.50, indicating a potential upside of 86.77%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Phathom Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclaris Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Phathom Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00

Aclaris Therapeutics has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Phathom Pharmaceuticals has a net margin of -422.42% compared to Aclaris Therapeutics' net margin of -732.42%. Phathom Pharmaceuticals' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aclaris Therapeutics-732.42% -30.73% -22.74%
Phathom Pharmaceuticals -422.42%N/A -90.11%

Aclaris Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclaris Therapeutics$18.72M8.91-$132.07M-$1.39-1.11
Phathom Pharmaceuticals$55.25M11.84-$334.33M-$5.24-1.79

In the previous week, Aclaris Therapeutics and Aclaris Therapeutics both had 1 articles in the media. Aclaris Therapeutics' average media sentiment score of 0.77 beat Phathom Pharmaceuticals' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aclaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Phathom Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Aclaris Therapeutics beats Phathom Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACRS vs. The Competition

MetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$157.01M$2.39B$5.51B$8.96B
Dividend YieldN/A1.80%5.25%4.02%
P/E Ratio-1.119.2628.0520.15
Price / Sales8.91771.14438.14127.85
Price / CashN/A161.3437.0657.97
Price / Book1.074.638.125.62
Net Income-$132.07M$31.26M$3.16B$248.50M
7 Day Performance6.21%6.81%4.40%5.54%
1 Month Performance3.36%4.31%4.09%7.52%
1 Year Performance22.22%3.88%34.53%22.06%

Aclaris Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACRS
Aclaris Therapeutics
2.6211 of 5 stars
$1.54
+6.2%
$9.71
+530.8%
+14.2%$157.01M$18.72M-1.11100
PHAT
Phathom Pharmaceuticals
3.3195 of 5 stars
$8.66
-2.9%
$17.50
+102.1%
-13.5%$622.74M$55.25M-1.65110
RLAY
Relay Therapeutics
2.5453 of 5 stars
$3.55
-2.2%
$17.67
+397.7%
-44.6%$622.34M$10.01M-1.59330
ABUS
Arbutus Biopharma
1.433 of 5 stars
$3.14
-3.1%
$5.50
+75.2%
-2.5%$620.55M$6.17M-7.6690
TNGX
Tango Therapeutics
2.233 of 5 stars
$5.43
-4.7%
$12.20
+124.7%
-35.8%$617.85M$40.99M-4.4590
CDXC
ChromaDex
3.1851 of 5 stars
N/A$9.03
+∞
N/A$611.50M$99.60M787.29120
DNTH
Dianthus Therapeutics
1.5622 of 5 stars
$18.25
-3.2%
$53.00
+190.4%
-35.4%$606.22M$6.24M-6.3480
MENS
Jyong Biotech
N/A$7.81
-1.6%
N/AN/A$603.66MN/A0.0031Gap Up
High Trading Volume
MGTX
MeiraGTx
4.4219 of 5 stars
$7.74
+3.1%
$24.00
+210.1%
+97.3%$603.54M$33.28M-3.34300News Coverage
Insider Trade
UPB
Upstream Bio
1.8252 of 5 stars
$10.98
-2.0%
$56.50
+414.6%
N/A$602.49M$2.37M0.0038News Coverage
XNCR
Xencor
3.9813 of 5 stars
$7.94
-5.7%
$28.00
+252.6%
-54.5%$599.26M$110.49M-2.59280

Related Companies and Tools


This page (NASDAQ:ACRS) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners